Tumor-infiltrating lymphocytes clinical experience

Cancer Journal (United States)

Volumn 21, Issue 6, 2015, Pages 465-469

  Besser, Michal J ^a,b   Shapira Frommer, Ronnie ^a   Schachter, Jacob ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adoptive cell therapy; Cancer; Clinical trials; Melanoma; Neoantigen; Tumor infiltrating lymphocytes

Indexed keywords

INTERLEUKIN 2;

ADOPTIVE CELL THERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL THERAPY; HUMAN; METASTATIC MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; ADOPTIVE IMMUNOTHERAPY; IMMUNOLOGY; PROCEDURES;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING;

EID: 84948427292     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000154     Document Type: Review

References (39)

1. +) T cell compartment in melanoma patients. Oncoimmunology. 2012; 1: 409-418.
2. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015; 348: 69-74.
3. Robbins PF, Lu Y-C, El-Gamil M, et al.Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumorreactive T cells. Nat Med. 2013; 19: 747-752.
4. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.NEngl JMed. 1988; 319: 1676-1680.
5. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994; 86: 1159-1166.
6. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298: 850-854.
7. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23: 2346-2357.
8. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26: 5233-5239.
9. Hong JJ, Rosenberg SA, Dudley ME, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res. 2010; 16: 4892-4898.
10. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17: 4550-4557.
11. Tseng J, Citrin DE, Waldman M, et al. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer. 2014; 120: 1426-1432.
12. Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumorinfiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012; 18: 6758-6770.
13. Pilon-Thomas S, Kuhn L, Ellwanger S, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012; 35: 615-620.
14. Tran KQ, Zhou J, Durflinger KH, et al. Minimally cultured tumorinfiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008; 31: 742-751.
15. + enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010; 16: 6122-6131.
16. +-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013; 31: 2152-2159.
17. Besser MJ, Shapira-Frommer R, Itzhaki O, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013; 19: 4792-4800.
18. BesserMJ, Itzhaki O, Shapira R, et al. Adoptive cell therapy with tumor infiltrating lymphocytes: clinical results and correlation to clinical success. Presented at the Society for Melanoma Research; Nov. 14, 2014; Zurich, Switzerland.
19. Ullenhag GJ, Sadeghi AM, Carlsson B, et al. Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. Cancer Immunol Immunother. 2012; 61: 725-732.
20. Wu R, Forget MA, Chacon J, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 2012; 18: 160-175.
21. Ellebaek E, Iversen TZ, Junker N, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients. J TranslMed. 2012; 10: 169.
22. Joseph RW, Peddareddigari VR, Liu P, et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011; 17: 4882-4891.
23. Chacon JA, Pilon-Thomas S, Sarnaik AA, et al. Continuous 4-1BB costimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology. 2013; 2: e25581.
24. Crompton JG, SukumarM, Roychoudhuri R, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015; 75: 296-305.
25. Quattrocchi KB, Miller CH, Cush S, et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol. 1999; 45: 141-157.
26. Goedegebuure PS, DouvilleLM, LiH, et al. Adoptive immunotherapywith tumor-infiltrating lymphocytes and interleukin-2 in patientswithmetastatic malignant melanoma and renal cell carcinoma: a pilot study. J ClinOncol. 1995; 13: 1939-1949.
27. Bukowski RM, SharfmanW, Murthy S, et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res. 1991; 51: 4199-4205.
28. Kradin RL, Kurnick JT, Lazarus DS, et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1989; 1: 577-580.
29. Ratto GB, Zino P, Mirabelli S, et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer. 1996; 78: 244-251.
30. Fujita K, Ikarashi H, Takakuwa K, et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res. 1995; 1: 501-507.
31. Freedman RS, Edwards CL, Kavanagh JJ, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol. 1994; 16: 198-210.
32. Li J, Chen QY, He J, et al. Phase I trial of adoptively transferred tumorinfiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology. 2015; 4: e976507.
33. Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014; 515: 572-576.
34. Lu YC, Yao X, Crystal JS, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014; 20: 3401-3410.
35. Lu YC, Yao X, Li YF, et al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol. 2013; 190: 6034-6042.
36. + T cells in human melanoma. Nat Med. 2015; 21: 81-85.
37. + T cells in a patient with epithelial cancer. Science. 2014; 344: 641-645.
38. Stevanović S, DraperLM, LanghanMM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015; 33: 1543-1550.
39. Chandran SS, Paria BC, Srivastava AK, et al. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin Cancer Res. 2015; 21: 534-543.